Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 15, 2006 Rich Duprey	Eisai Eyes Alzheimer's Market Japan's Eisai Pharmaceuticals launches another challenge to Forest Labs' Alzheimer's drug. Investors, take note.
The Motley Fool May 23, 2006 Rich Duprey	Eisai Has a Yen for Profits With new formulations for its current drugs planned for release, expansion of its blockbuster drug Aricept possible, and with a few new drugs in the pipeline, the Japanese pharmaceutical is poised to continue churning out record revenues and earnings that investors won't soon forget.
The Motley Fool October 18, 2006 Rich Duprey	FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note.
The Motley Fool April 17, 2007 Rich Duprey	Eisai Says Sayonara The Japanese company withdraws its application for approval of its Alzheimer's drug for severe cases of the disease in Europe. What will it mean to investors?
The Motley Fool November 2, 2006 Rich Duprey	Eisai Profits From Demand The Japanese pharmaceutical reports strong profits on increased demand for Alzheimer's treatment. Investors, take note.
The Motley Fool September 2, 2005 Rich Duprey	An Opportunity Not to Forget Japanese pharmaceutical Eisai targets another segment of the growing Alzheimer's market. Investors, take note.
The Motley Fool January 21, 2005 Rich Duprey	Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all.
The Motley Fool August 27, 2007 Rich Duprey	Japan Is Serious About Alzheimer's While Britain limits access, Japan expands coverage of the top-selling treatment for Alzheimer's. Japan's regulators made the decision following a six-month study comparing Aricept with a placebo.
The Motley Fool March 31, 2008 Rich Duprey	Teva's Tough Pill to Swallow Eisai wins a preliminary injunction against Teva's generic Alzheimer's treatment.
The Motley Fool March 17, 2006 Rich Duprey	Eisai's Dementia Problems Clinical trials for expanded use of the Japanese pharma's top-selling drug reveal higher incidences of death. Aricept is already approved for vascular dementia in several countries, but it would seem that FDA approval for use here won't be coming any time soon. Investors, take note.
The Motley Fool August 13, 2007 Rich Duprey	U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept.
The Motley Fool June 29, 2007 Rich Duprey	No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment.
The Motley Fool December 12, 2005 Rich Duprey	Patent? What Patent? Japanese drug firm Eisai sues Teva over a patented Alzheimer's treatment. Investors, take note.
The Motley Fool November 23, 2004 Rich Duprey	Backyard Treasure Hunts Not every busy backyard venture will be a profitable seven-bagger investment, but here is some good advice on looking in one's own backyard for investment possibilities.
The Motley Fool January 10, 2007 Rich Duprey	Foolish Forecast: Greener Forest Labs The pharmaceutical firm stands tall against competition. When the company releases its third-quarter 2007 financials, investors shouldn't have to reach for their medicine chest.
The Motley Fool September 5, 2008 Brian Lawler	Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon.
The Motley Fool May 15, 2007 Rich Duprey	Eisai Doles Out Tough Medicine The Japanese pharmaceutical company wins a patent infringement decision regarding its heartburn treatment. Investors, take note.
The Motley Fool October 13, 2006 Rich Duprey	NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost.
The Motley Fool March 26, 2007 Rich Duprey	Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note.
The Motley Fool May 30, 2006 Rich Duprey	NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders?
The Motley Fool October 10, 2011 Frank Vinluan	TRGT Tries Again With Alzheimer's Disease Drug Candidate A Targacept compound that has been studied in a range of cognitive disorders with drug partner AstraZeneca has started in mid-stage clinical studies as a potential new Alzheimer's disease treatment.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool February 8, 2005 Charly Travers	Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company
The Motley Fool April 11, 2011 Brian Orelli	Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected.
The Motley Fool January 20, 2006 Rich Duprey	Generics Give Originators Heartburn Eisai, the Japanese manufacturer of an acid reflux remedy, sees a generic maker win FDA approval. What does this mean for investors?
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
Pharmaceutical Executive February 1, 2006 Alana Klein	Thought Leader: Q&A with Ed Broughton Eisai executive Ed Broughton discusses new business opportunities, and what types of partnerships are up next for the growing pharmaceutical company.
The Motley Fool March 11, 2010 Jim Mueller	Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices?
The Motley Fool May 28, 2010 Brian Orelli	Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree.
The Motley Fool January 19, 2011 Brian Orelli	High Stakes at Tomorrow's FDA Panel Meeting It's more than just Eli Lilly on the line.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool March 3, 2010 Brian Orelli	A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%.
The Motley Fool March 7, 2007 Rich Duprey	Eisai Courts Danger The start of a patent-infringement trial sets the stage for the Japanese pharmaceutical's loss of protection on a major drug.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
The Motley Fool December 18, 2009 Brian Orelli	Swine Flu Just Isn't Bringing Home the Bacon Looks like that one-time boost from sales of swine flu vaccine may not add much to the bottom lines of vaccine makers like GlaxoSmithKline, AstraZeneca, sanofi-aventis, and Novartis.
The Motley Fool March 18, 2011 Brian Orelli	Forget Getting Approved, for Now The FDA wants more information on Eli Lilly's Amyvid.
The Motley Fool April 12, 2004 Brian Gorman	Forest Labs Faces Skeptics Its star drug Namenda, a new treatment for Alzheimer's disease, is taking heat from doctors.
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool January 17, 2012 Brian Orelli	You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again.
The Motley Fool September 7, 2005 Rich Duprey	Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note.
Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
The Motley Fool July 2, 2010 Brian Orelli	Arena Got Taken A billion-dollar market and that's all the pharmaceuticals company could get?
The Motley Fool April 24, 2007 Ryan Fuhrmann	Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note.
The Motley Fool August 4, 2010 Mac Greer	One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan.
The Motley Fool October 14, 2005 Rich Duprey	Chiron Ready to Fly Flu vaccine maker readies first shipments as flu season begins and avian flu fears rise.
The Motley Fool February 13, 2006 Rich Duprey	Killing Elan's Pain A deal with Eisai for severe painkiller Prialt may not be the pharmaceutical company's best move. Investors, take note.
The Motley Fool January 26, 2006 Rich Duprey	Will Acquisitions Patch Merck's Pipeline? The pharmaceutical giant announces a biotech shopping spree. A few key acquisitions that contribute late-stage drugs and significant revenue might be all Merck needs to keep its pipeline open. Investors, take note.
The Motley Fool October 31, 2005 Rich Duprey	Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.
The Motley Fool January 13, 2010 Brian Orelli	JPMorgan Challenge: On the Cusp of Greatness Development-stage drugmaker Medivation has a partner and is ready for phase 3 data to roll in.